Synthesis, Characterization, and Comprehensive In Vitro and In Silico Evaluation of the Anti‐Inflammatory Potential of Novel 1,2,3‐Triazole–Arylidenehydrazide/Thiazolidinone Hybrids
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.70081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Nihan Aktaş Pepe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology & Genetics, Faculty of Life & Natural Sciences, Abdullah Gül University, Kayseri, Türkiye. Hauptthemen laut MEDLINE: Triazoles, Thiazolidines, Anti-Inflammatory Agents, Non-Steroidal, Hydrazines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Five novel 1,2,3‐triazole/arylidenehydrazide/thiazolidinone hybrid compounds ( 7–11 ) were synthesized and characterized using NMR, HRMS, IR, and HPLC purity analysis. The cytotoxicity of these compounds was evaluated on fibroblasts and THP‐1 cells, showing that all compounds were nontoxic at the tested concentrations. The wound healing assay revealed that compounds 7 , 9 , and 10 significantly enhanced wound closure, with a 7.74%–32.69% improvement in treated cells. Compounds 8 and 11 showed moderate effects. Anti‐inflammatory activity was assessed through qRT‐PCR, demonstrating that compound 10 led to the most significant reduction in proinflammatory cytokines TNF‐α, IL‐1β, and NF‐κB1. In addition, the expression of Iba1 protein in THP‐1 cells confirmed that compound 8 showed the strongest anti‐inflammatory effect, surpassing that of aspirin. Compound 10 showed the highest inhibition of NF‐κB signaling and iNOS activity. Molecular docking studies revealed that compounds 10 and 11 had strong binding affinities to TNF‐α and iNOS, with compound 11 showing the most stable interactions. Molecular dynamics simulations supported these findings, indicating that compound 11 demonstrated more stable binding to both targets. Overall, the results suggest that compounds 10 and 11 are promising anti‐inflammatory candidates with potential for further development in therapeutic applications for inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology & Genetics, Faculty of Life & Natural Sciences, Abdullah Gül University, Kayseri, Türkiye.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, Türkiye.
- Department of Organic Agriculture Management, Pamukkale University, Denizli, Türkiye.
- Department of Biology, Faculty of Science, Pamukkale University, Denizli, Türkiye.
ORCID-Profile: Furkan Çakır, Büşra Acar, Alaattin Şen, Halil Şenol
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Pepe, N. A., Çakır, F., Atalay, T., Acar, B., Turgut, G. Ç., Şen, A., & Şenol, H. (2025). Synthesis, Characterization, and Comprehensive In Vitro and In Silico Evaluation of the Anti‐Inflammatory Potential of Novel 1,2,3‐Triazole–Arylidenehydrazide/Thiazolidinone Hybrids. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70081
Vancouver
Pepe NA, Çakır F, Atalay T, Acar B, Turgut GÇ, Şen A, et al. Synthesis, Characterization, and Comprehensive In Vitro and In Silico Evaluation of the Anti‐Inflammatory Potential of Novel 1,2,3‐Triazole–Arylidenehydrazide/Thiazolidinone Hybrids. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70081
BibTeX
@article{Pepe2025,
author = {Pepe, Nihan Aktaş and Çakır, Furkan and Atalay, Tuğba and Acar, Büşra and Turgut, Gurbet Çelik and Şen, Alaattin and Şenol, Halil},
title = {Synthesis, Characterization, and Comprehensive In Vitro and In Silico Evaluation of the Anti‐Inflammatory Potential of Novel 1,2,3‐Triazole–Arylidenehydrazide/Thiazolidinone Hybrids},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.70081}
}
EUVIMED